ReviewResearch and reports in tropical medicine2018
Elimination of lymphatic filariasis: current perspectives on mass drug administration.
Review in Research and reports in tropical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Community views on mass drug administration for filariasis: a qualitative evidence synthesis.The Cochrane database of systematic reviews · 2022Pooled it
- Effect of Adding a Six-Week Course of Doxycycline to Intensive Hygiene-Based Care for Improving Lymphedema in a Rural Setting of Mali: A Double-Blind, Randomized Controlled 24-Month Trial.The American journal of tropical medicine and hygiene · 2024Trial
- Trial
- Comprehensive evaluation of stool-based diagnostic methods and benzimidazole resistance markers to assess drug efficacy and detect the emergence of anthelmintic resistance: A Starworms study protocol.PLoS neglected tropical diseases · 2018Trial
- Two decades of filariasis in India: Insights into prevalence, diagnostic challenges, and strategies for elimination by 2027.IJID regions · 2025Review
- Exploring drug coverage variability within districts: A CES approach to investigate treatment gaps in Mozambique's schistosomiasis program.PLoS neglected tropical diseases · 2025Article
- Article
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Sensitivity of anti-filarial antibodies for lymphatic filariasis surveillance: Insights from a serological survey in Samoa in 2018.PLoS neglected tropical diseases · 2025Article
- Using community-based participatory approaches to improve access to mass drug administration for trachoma elimination in a pastoral conflict area of Kenya.PLoS neglected tropical diseases · 2024Article
- Towards Understanding the Microepidemiology of Lymphatic Filariasis at the Community Level in Ghana.Tropical medicine and infectious disease · 2024Article
- Modelling the cost of engage & treat and test & treat strategies towards the elimination of lymphatic filariasis in Ghana.PLoS neglected tropical diseases · 2024Article
- Identification and prioritisation of potential vaccine candidates using subtractive proteomics and designing of a multi-epitope vaccine against Wuchereria bancrofti.Scientific reports · 2024Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- A Landscape on Lymphatic Filariasis with its Effects and Recent Advanced Treatments.Recent advances in anti-infective drug discovery · 2024Review
- Article
- Mapping resistance-associated anthelmintic interactions in the model nematode Caenorhabditis elegans.PLoS neglected tropical diseases · 2023Article
- Antibiotic resistance andHealth science reports · 2023Article
- Lymphatic filariasis in Zambia: A scoping review protocol.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Following the London declaration on neglected tropical diseases (NTDs) in 2012 and inspired by the WHO 2020 roadmap to control or eliminate NTDs, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) intensified preventive chemotherapy and management of morbidity as the two main strategies to enhance progress towards the elimination of lymphatic filariasis (LF). This paper focuses on current perspectives of mass drug administration (MDA) towards the elimination of LF. The goal of MDA is to reduce the density of parasites circulating in the blood of infected persons and the intensity of infection in communities to levels where transmission is no longer sustainable by the mosquito vector. Three drugs, diethylcarbamazine, albendazole, and ivermectin are currently available for LF treatment, and their effectiveness and relative safety have opened the possibility of treating the entire population at risk. Currently, almost all LF endemic countries rely on the single-dose two-drug regimen recommended by the GPELF to achieve elimination. The 4th WHO report on NTDs has indicated that considerable progress has been made towards elimination of LF in some countries while acknowledging some challenges. In this review, we conclude that the 2020 elimination goal can be achieved if issues pertaining to the drug distribution, health system and implementation challenges are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.